Delivery Order SPE2D018D0005-SPE2D325F090A
Award Date 5/28/25
Potential Completion Date 6/2/25
Potential Value $4.6K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Raritan, NJ 08869, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Ortho-Clinical Diagnostics, Inc. has been awarded a delivery order contract by the Defense Medical Supply Chain with a ceiling value of $1,767.32 for Rght Anti-A B Bcln 10ml Btl Orth Bb—a specialized blood bank diagnostic reagent. The contract award is dated July 18, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the company's facility in Raritan, New Jersey. This delivery order employs fixed-price contracting with economic price adjustment and was awarded...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,963.68 by the Defense Medical Supply Chain on August 5, 2025, for Rgt Anti-A B Bcln 10mL bottles used in orthopedic blood bank applications. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating open competition, and carries an ultimate completion date of August 8, 2025. Performance will be conducted at the awardee's facility in...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $5,532.10 by the Defense Health Agency's Medical Supply Chain on September 26, 2025, for a RGT Anti-D BCLN 150ML MNCLN ABO GRP BB product. This fixed-price delivery order with economic price adjustment carries an ultimate completion date of October 1, 2025, and will be performed in Raritan, New Jersey. The award was made without a set-aside designation, indicating open competition among...
- The U.S. Defense Department's Medical Supply Chain agency awarded a delivery order valued at $1,109.97 to Ortho-Clinical Diagnostics, Inc. for Anti-B Bioclone 15x10ML on August 11, 2025, with completion targeted for August 14, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, indicating open competition. Ortho-Clinical Diagnostics, headquartered in Raritan, New Jersey, is a for-profit medical equipment manufacturer specializing...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order valued at $1,832.54 by the Defense Department's Medical Supply Chain on August 5, 2025, for the delivery of Ortho Anti-A Blood Clone 150ML Monoclonal ABO Group BB reagent. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating open competition, and is scheduled for ultimate completion by August 8, 2025. Performance will take place at the company's facility in Raritan, New Jersey....
- The Defense Department's Medical Supply Chain has awarded a delivery order valued at $4.7K to Ortho-Clinical Diagnostics, Inc. for blood group serum, effective June 2, 2025, with an ultimate completion date of June 23, 2025. This fixed-price delivery order with economic price adjustment provisions will be performed at the contractor's facility in Raritan, New Jersey. The contract was awarded without set-aside designations, indicating open competition among qualified vendors. Ortho-Clinical...
- Ortho-Clinical Diagnostics, Inc., headquartered in Raritan, New Jersey, was awarded a delivery order valued at $1,910.02 on August 6, 2025, for Anti-A Bioclone 15x10ml medical diagnostic reagents. The contract, which will be completed by August 27, 2025, was issued without a set-aside designation, indicating open competition. The funding originates from the Medical Supply Chain within the Department of Defense, with the place of performance located in Raritan, New Jersey. This delivery order...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $1,037.23 to Ortho-Clinical Diagnostics, Inc. for Reagent Anti-D Bioclone 150ML Monoclonal on September 3, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating open competition. The award will be performed at the contractor's facility in Raritan, New Jersey, with an ultimate completion date of September 8, 2025. Ortho-Clinical Diagnostics, Inc., a for-profit medical...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order valued at $1,871.28 for Anti-A Bioclone 15x10ml on July 21, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes fixed-price pricing with economic price adjustment and was awarded without a set-aside designation, indicating open competition. The work will be performed in Raritan, New Jersey, and is funded by the Defense Health Agency's Medical Supply Chain, which supports critical medical diagnostic...
- Ortho-Clinical Diagnostics, Inc. was awarded a delivery order contract on September 5, 2025, by the Defense Medical Supply Chain for the supply of Reagent Anti-D Bioclone 150mL Monoclonal with a ceiling value of $1,037.23. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and will be performed at the company's facility in Raritan, New Jersey. No set-aside designation was used for this award, indicating it was competed openly. The contract...